Skip to content

Research & Development

Pharmaceutical Pipeline

Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence

Avicanna has created a pipeline of patent-pending drug candidates which are indication-specific and in various stages of clinical development and commercialization.

These cannabinoid-based drug candidates provide solutions for unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders.

Established Research & Development Platform

Setting the Standard in the Cannabinoid Industry on Advanced and Evidence-Based Products

R&D headquarters at JLABS @ Toronto, Johnson & Johnson Innovation Centre in the MaRS Discovery District
Drug development pipeline, including sustained release tablets, transdermal patches and nano participle formulations

30+

Commercial stage proprietary products

10+

Scientists

7+

Canadian Government research grants awarded since 2020

8+

Pending Patents

4+

4 Health Canada issued cannabis research licenses issued to Avicanna or institutional collaborators over the
past 4 years

Contact Us

World-Class Collaborations

R&D and Clinical Partnerships Over the Past 4 Years

World-Class Collaborations

R&D collaborations with world-class academic and clinical institutes

Avicanna counts with collaborations with world-class academic and clinical institutes Including 4 Health Canada cannabis R&D licenses issued to Avicanna and its academic collaborators.

MaRS Discovery
District

University Health
Network

Hospital of
Sick Children

University of
Guelph

JLABS @ Toronto

University of
Toronto

Sunnybrook Health
Science Centre

Clinical Development

Setting the Standard in the Cannabinoid Industry on Advanced and Evidence-Based Products